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Abstract
Purpose MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour 
progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic 
value of MMP9 and its association with cytoskeletal modulators in early-stage invasive breast cancer (BC).
Methods MMP9 expression was evaluated by immunohistochemistry using a well-characterised series of primary BC 
patients with long-term clinical follow-up. Association with clinicopathological factors, patient outcome and ECM remod-
elling BC-biomarkers were investigated. METABRIC dataset, BC-GenExMiner v4.0 and TCGA were used for the external 
validation of MMP9 expression. GSEA gene enrichment analyses were used to evaluate MMP9 associated pathways.
Results MMP9 immunopositivity was observed in the stroma and cytoplasm of BC cells. Elevated MMP9 protein levels 
were associated with high tumour grade, high Nottingham Prognostic Index, and hormonal receptor negativity. Elevated 
MMP9 protein expression correlated significantly with cytokeratin 17 (Ck17), Epidermal Growth Factor Receptor (EGFR), 
proliferation (Ki67) biomarkers, cell surface adhesion receptor (CD44) and cell division control protein 42 (CDC42). Cyto-
plasmic MMP9 expression was an independent prognostic factor associated with shorter BC-specific survival. In the external 
validation cohorts, MMP9 expression was also associated with poor patients’ outcome. Transcriptomic analysis confirmed 
a positive association between MMP9 and ECM remodelling biomarkers. GSEA analysis supports MMP9 association with 
ECM and cytoskeletal pathways.
Conclusion This study provides evidence for the prognostic value of MMP9 in BC. Further functional studies to decipher 
the role of MMP9 and its association with cytoskeletal modulators in BC progression are warranted.
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TCGA  The cancer genome atlas
TNBC  Triple negative breast cancer
Introduction
Matrix metalloproteinases (MMPs) are a family of proteases 
that have multiple biological functions in cancer develop-
ment and progression and are abundantly up regulated 
in breast cancer (BC). MMP9, also known as gelatinase 
B, plays an important role in extracellular matrix (ECM) 
remodelling, protein cleavage, and is associated with tumour 
invasion, metastasis and modulation of tumour microenvi-
ronment [1, 2]. MMP9 has the capability to degrade col-
lagens, including Type IV collagen [3], which plays a role 
in basement membrane degradation promoting migration, 
invasion and metastases.
MMP9 is secreted as an inactive pro-enzyme and acti-
vation of latent MMP9 is the critical step in its regulation 
[4]. In vitro and in vivo experiments in human and experi-
mental models of cancers reveal that the increased MMP9 
expression is related to tumour progression [5, 6]. MMP9 
expression is regulated by several molecular pathways such 
as extracellular signal-regulated kinase (ERK), mitogen-
activated protein kinase (MAPK), and phosphoinositide-
3-kinase–protein kinase (PI3K); pathways recognised to be 
altered in BC [7]. In BC, increased epidermal growth fac-
tor receptor (EGFR) expression, which is a poor prognostic 
marker, is implicated with up-regulation of MMP9 [8]. The 
regulation of the MMPs, particularly MMP9, by p53 has also 
been documented [9].
MMP9 is activated by the Cell Division Cycle 42 
(CDC42), a Rho GTPase family member, which plays a 
major role in ECM adhesion and cytoskeletal organisation. 
Elevated CDC42 expression in BC dysregulates the epi-
thelial architecture, which may initiate oncogenes. CDC42 
gene silencing studies in BC xenografts showed that CDC42 
knockdown decreased the tumour cell invasion and metas-
tasis in vivo [10]. In addition, CDC42 activation stimulated 
trafficking of membrane-type 1 matrix metalloproteinase 
(MT1-MMP) in BC cells [11].
CD44 is a transmembrane glycoprotein cell surface adhe-
sion receptor that promotes the secretion of active MMP9. 
MMP9 gene silencing is shown to change the expression of 
CD44 and significantly decreases migration and invasion of 
tumour cells [12]. Increased MMP9 mRNA expression was 
also observed in  CD44+ BC cells compared to  CD44− cells. 
In vitro experiments showed that, inhibition of the CD44-
MMP axis may provide therapeutic targets for reducing the 
tumour spread which further establishes a positive associa-
tion between MMP9 and CD44 expression [10]. Thus, these 
studies support a role for CD44 in regulating MMP9 and is 
strongly associated with aggressively behaving tumours. In 
addition, MMP9 is part of the Rosetta poor-prognosis sig-
nature for BC [13] and in silico analysis of BC DNA micro-
array datasets also showed a positive association of MMP9 
with poor outcomes [14]. For these reasons in this study 
we investigated the association between MMP9, cytoskel-
etal modulators, and clinicopathological factors of BC at the 




This study obtained ethics approval by the North 
West–Greater Manchester Central Research Ethics Com-
mittee under the title; Nottingham Health Science Biobank 
(NHSB), reference number 15/NW/0685. All samples from 
Nottingham used in this study were pseudo-anonymised 
and collected prior to 2006 and stored in compliance with 
the UK Human Tissue Act. MMP9 protein expression was 
evaluated using a well-characterised cohort of early-stage 
(operable) primary invasive BC (n = 675) treated in Notting-
ham University Hospital NHS Trust as previously described 
[15]. Clinical and pathological data of patients (including 
hormone receptor status, histological tumour type, tumour 
grade, tumour size, lymph node status, Nottingham Prognos-
tic Index and lymphovascular invasion (LVI)) were availa-
ble. Tumour types were revisited and coded according to the 
recent WHO blue book [16]. BC-specific survival (BCSS) 
was maintained on a prospective basis. The expression of a 
large panel of BC progression/metastasis-related biomark-
ers, including the Ki67 [17], EGFR [18], CDC42 [19], CD44 
[20], PIK3CA [21] and basal marker (cytokeratin 5/6 and 
17) [22], was also studied. BC molecular subtypes based 
on the IHC profile of Oestrogen Receptor (ER), Progester-
one Receptor (PR) and Human Epidermal Growth Factor 2 
(HER2) were defined as previously described [23]: Luminal 
A: ER+/HER2− Low Proliferation (Ki67 < 10%), Luminal 
B: ER+/HER2− High Proliferation (Ki67 ≥ 10%) or ER +/
HER2 + , HER2-positive class: HER2 + regardless of ER 
status, Triple Negative Breast Cancer (TNBC): exhibiting 
negative expression of ER, PR, and HER2.
The clinicopathological significance of MMP9 mRNA 
expression, copy number alterations, differential gene 
expression analysis (DGE), and pathway analysis were 
assessed using the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) dataset (n = 1980 
BC cases) [24]. External validation was performed using 
the Breast Cancer Gene-Expression Miner v4.0 (BC-Gen-
ExMiner v4.0) [15, 25] and The Cancer Genome Atlas 
(TCGA) [26] as previously described.
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Immunohistochemistry
Specificity of MMP9 antibody was validated by western 
blotting prior to immunohistochemistry. Cell lysates blots 
of HEK293 and MCF7 cell lines which were used as posi-
tive and negative controls respectively (obtained from the 
American Type Culture Collection; Rockville, MD, USA) 
were incubated with anti-MMP9 antibody (Rabbit mono-
clonal [EP1254], Abcam) at 1:800 dilution for overnight 
(4 °C) and bands were detected using fluorescent second-
ary antibodies at (1:15,000) (IR Dye 800CW donkey anti-
rabbit and 680RD donkey anti-mouse, LI-COR Biosciences, 
UK). Mouse β-Actin (A5441, Sigma-Aldrich; Clone AC-15; 
Sigma, UK) at 1:5000 was used as a house-keeping protein. 
Blocking and visualisation were done as previously docu-
mented [27]. The specificity of the antibody was validated 
with a single specific band at the predicted molecular weight 
(70 kDa, Supplementary Fig. 1a).
Tumour samples were arrayed onto tissue microarrays 
(TMAs) as previously described [28]. Full-face BC tissue 
sections and TMAs were immunoassayed using Novolink 
Max Polymer Detection system (Leica, Newcastle, UK). 
In brief, 4 µm BC tissue sections were deparaffinised with 
xylene and rehydrated through 100% ethanol. Heat-induced 
(pH6) citrate antigen retrieval was performed and MMP9 
antibody (1:100) was incubated for overnight at 4 °C. 3-3′ 
Diaminobenzidine tetrahydrochloride (Novolink DAB sub-
strate buffer plus) was used as the chromogen. Slides were 
counterstained with Novolink haematoxylin for 6 min, dehy-
drated and cover slipped. Normal kidney tissue was used as 
a positive tissue control, whereas no primary antibody was 
used as a negative control.
TMA slides were digitally scanned at 20X magnification 
and viewed using NanoZoomer NDP viewer (Hamamatsu 
Photonics, Welwyn Garden City, UK). Both the percent-
age of staining and staining intensity of MMP9 cytoplasmic 
expression in invasive tumour cells and stromal cells were 
individually assessed to calculate the final histochemical 
score (H-score). Staining was double scored blindly by two 
researchers (NO and IMM) for 25% cores to assess inter-
observer concordance. Inter-observer agreement was deter-
mined, and the interclass correlation coefficient was 0.86, 
indicating an excellent concordance between scorers. Dis-
cordant cases were re-scored by both observers and a final 
score was agreed.
Statistical analysis
IBM SPSS 24.0 (SPSS IBM Corp, Chicago, IL, USA) soft-
ware was used for statistical analysis and reported in line 
with REMARK guidelines [29]. The MMP9 H-score was 
dichotomised into high and negative/low expression using 
the median cut-point value. Chi-squared test was used to 
evaluate the association between MMP9 expression and the 
clinicopathological parameters.
Kaplan–Meier analysis with log-rank test for significance 
was performed to assess BCSS. Cox multivariate analysis 
was performed to test independence from standard prognos-
tic factors in BC (nodal stage, tumour grade, tumour size, 
ER level of expression, and Ki67). A p value of < 0.05 was 
considered significant.
Gene expression was analysed in the subset of META-
BRIC patients for which MMP9 expression was available. 
DGE between A) low Vs high MMP9 cytoplasmic expres-
sion, and B) low Vs high MMP9 stromal expression were 
calculated using the Robina implementation of Edge-R 
statistical tool [30] and DGE with > twofold-change, and 
adjusted p values < 0.05 were considered significant. The 
DGE were examined using the online WebGestalt platform 
and adjusted p < 0.01 considered statistically significant [31, 
32] and significantly enriched gene ontologies common for 
both cytoplasmic and stromal MMP9 protein expression. 
Furthermore, Venny 2.0 [33] was used to identify the over-
lapping DGEs common to both the cytoplasmic and stromal 
MMP9 protein expression.
Results
MMP9 protein expression in BC
Full-face BC tissue (n = 10) sections were used to evaluate 
the pattern of MMP9 protein expression prior to staining of 
TMAs. This showed uniformly weak MMP9 expression in 
normal glandular epithelium (Fig. 1a) and ductal carcinoma 
in situ (DCIS; Fig. 1b). There was slightly increased immu-
noreactivity of MMP9 observed in the co-existing invasive 
BC cells (Fig. 1c), in the intravascular tumour cell emboli 
(Fig. 1d), stromal expression (Fig. 1e) and Fig. 1f show-
ing No Primary Antibody Control. MMP9 cytoplasmic and 
stromal protein expression (C+/S+) showed a positive cor-
relation with MMP9 mRNA (Spearman’s coefficient 0.218; 
p = 0.027), this association was confirmed using TCGA data 
[34, 35] (Supplementary Fig. 1b).
On BC  TMAs, a variable degree of MMP9 protein 
expression was observed (Fig. 1g–k). The H-scores of both 
cytoplasmic and stromal expressions did not follow a nor-
mal distribution. Therefore, for dichotomisation into nega-
tive/low and high expression, the median H-scores (0 and 
50, respectively) were used. Out of 675 informative TMA 
cores, 71% showed negative/low expression in the cytoplasm 
(Fig. 1g) while 29% showed high expression (Fig. 1h). In the 
stroma 53% showed negative/low expression (Fig. 1i), while 
47% showed high expression (Fig. 1j). Positive immunore-
activity was observed in human kidney sections (Fig. 1k). 
 Breast Cancer Research and Treatment
1 3
H-scores for cytoplasmic and stromal staining showed a 
positive correlation (Spearman’s coefficient 0.1; p = 0.020).
Elevated MMP9 cytoplasmic and stromal staining were 
associated with high tumour grade (p < 0.0001), poor Not-
tingham Prognostic Index (NPI) (p < 0.0001; Table 1), hor-
mone receptor negativity (p < 0.01), among IHC subtypes 
associated with TNBC and HER2 + tumours (p = 0.002). 
High stromal MMP9 expression additionally showed asso-
ciation with LVI positivity (p = 0.046; Table 1). High MMP9 
expression positively associated with proliferation marker 
Ki67 (p = 0.004), signalling pathway associated markers; 
EGFR (p = 0.024) and PIK3CA (p = 0.039), cytoskeleton 
remodelling markers; CDC42 and CD44 (p < 0.003 and 
p = 0.025, respectively). High cytoplasmic MMP9 showed 
positive association with basal cytokeratin CK17 (p = 0.001; 
Table 2) and revealed a low expression in lobular and special 
type tumours (p = 0.003). 
BCSS of patients with tumours expressing high cytoplas-
mic MMP9 was significantly shorter than that of the nega-
tive/low expression subgroup (p = 0.013; HR = 1.5; 95%CI 
1.1–2.0; Fig. 2a). Stromal MMP9 also showed a similar 
trend but did not reach significance (p = 0.058; HR = 1.3; 
95%CI 0.9–1.8; Fig. 2b). Combined MMP9 cytoplasmic and 
stromal (CS) survival analysis demonstrated that tumours 
with high cytoplasmic and stromal expression were asso-
ciated with poor prognosis (p = 0.008; HR = 1.2; 95%CI 
1.0–1.4; Fig. 2c). In multivariate Cox regression analysis, 
cytoplasmic MMP9 expression on its own was an inde-
pendent predictor of BCSS (p = 0.026; HR = 1.6; 95% 
CI 1.1–2.3; Table 3). There was no association between 
MMP9 protein and outcome in Luminal A and B, TNBC or 
HER2 + subgroups.
MMP9 genomic profiling
Consistent with the results obtained for MMP9 protein 
expression, in the METABRIC and TCGA datasets, MMP9 
copy number gain (14.0%) and high mRNA expression 
(50.1%) was associated with negative ER and PR status, high 
histological grade, and poor NPI (all; p < 0.01; Table 4). 
MMP9 copy number gain and high MMP9 mRNA expres-
sion was associated with poor prognostic METABRIC Inte-
grative clusters [24] such as 1, 5 and 9 (p < 0.0001). Asso-
ciations between MMP9 copy number alterations, mRNA 
expression and clinicopathological variables are summa-
rised in Table 4. External validation of the pooled data using 
Fig. 1  Immunohistochemical expression of MMP9 in BC. Morpho-
logical characteristics of MMP9 immunohistochemistry in Full-face 
breast cancer tissue (a–f). a Normal mammary gland and b DCIS 
showing absent or weak MMP9 staining. Showing high immunore-
activity in c invasive, and d LVI positive tumour samples. Showing 
high MMP9 stromal staining (e) and (f) no primary antibody control 
(negative control) in invasive breast carcinoma. All images are at 
50 µm. MMP9 protein expression in breast cancer TMA cores (g) and 
(h) showing low and high cytoplasmic (C+) expression while, i and j 
showing low and high stromal (S+) expression, respectively. The nor-
mal kidney tissue (k) section used as positive control. TMA cores are 
100 µm magnification
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BC-GenExMiner v4.0 was in agreement where high MMP9 
mRNA expression was associated with ER, and PR nega-
tivity, high histological grade (all; p < 0.001) and poor NPI 
(p < 0.01). In PAM50 subtypes, high MMP9 expression was 
associated with basal-like and HER2 + classes (p < 0.0001).
High MMP9 mRNA showed positive association with 
other MMPs (MMP1, MMP2, MMP7, MMP11, MMP14 and 
MMP15; all p = 0.0001), collagens [COL27A1; (p = 0.008), 
COL23A1 (p = 0.003) and COL11A2; (p = 0.045)], TGFβ1 
(p < 0.0001) and cytoskeletal remodelling biomarkers 
CDC42 (p = 0.004; Table 5). These associations were con-
firmed using BC-GenExMiner v4.0 (Supplementary Fig. 2) 
via gene targeted analysis.
In the METABRIC cohort, MMP9 copy number gain 
was associated with significantly shorter BCSS (p = 0.016; 
HR 1.3; 95%CI 1.1–1.7; Fig. 2d). Tumours expressing high 
MMP9 mRNA expression showed significantly shorter 
BCSS than the low expression subgroup (p < 0.0001; 
HR = 1.5; 95%CI 1.2–1.8; Fig. 2e). Pooled MMP9 gene 
expression data (n = 2071) in BC-GenExMiner v4.0 con-
firmed the association of high MMP9 expression with poorer 
outcome (p = 0.007; HR = 1.3; 95%CI 1.1–1.5; Fig. 2f) and 
in agreement with protein expression results. In multivariate 
Cox regression analysis, MMP9 mRNA was an independent 
predictor of BCSS (p = 0.048; HR = 1.3; 95% CI 1.0–1.6) 
independent of the standard prognostic parameters of BC 
Table 1  Associations between MMP9 protein expression and clinicopathological features in the whole Cohort
Significant p values are highlighted in bold; GPG; Good Prognostic Group; MPG: Moderate Prognostic Group; PPG: Poor Prognostic Group
* Medullary like carcinoma was renamed as Ductal NST carcinoma according to the recent WHO book 2019 and added to the ductal NST group










Age at diagnosis (years)
  < 50 172 (70.5) 72 (29.5) 0.740
(0.110)
143 (58.0) 101 (42.0) 0.019
(5.543)  ≥ 50 309 (71.7) 122 (28.3) 212 (49.0) 219 (51.0)
Histological grade
 1 76 (84.0) 14 (16.0)  < 0.0001
(20.570)
61 (68.0) 29 (32.0)  < 0.0001
(27.165) 2 177 (78.0) 51 (22.0) 141 (62.0) 87 (38.0)
 3 225 (64.0) 125 (36.0) 153 (44.0) 197 (56.0)
Stage
 I 303 (74.0) 105 (26.0) 0.081
(6.743)
226 (55.0) 182 (46.0) 0.012
(11.005) II 138 (67.0) 69 (33.0) 106 (51.0) 101 (19.0)
 III 37 (70.0) 16 30.0) 23 (43.0) 30 (57.0)
Tumour size
 < 2.0 cm 234 (74.0) 81 (26.0) 0.137
(2.206)
170 (54.0) 145 (46.0) 0.604
(1.269)  ≥ 2.0 cm 246 (69.0) 110 (31.0) 185 (52.0) 171 (48.0)
Histological type
 Ductal including NST* 406 (69.2) 181 (30.8) 0.003
(11.586)
300 (51.1) 287 (48.9) 0.092
(4.88) Lobular 48 (87.0) 7 (13.0) 34 (62.0) 21 (38.0)
 Special type 22 (88.0) 3 (12.0) 17 (68.0) 8 (32.0)
IHC subtypes
 ER+/HER2-low proliferation 115 (81.0) 26 (19.0) 0.002
(14.857)
85 (60.3) 56 (40.0) 0.001
(15.879) ER+/HER2− high proliferation 154 (72.0) 60 (28.0) 126 (59.0) 88 (41.0)
 Triple negative 80 (64.0) 45 (36.0) 51 (40.0) 74 (60.0)
HER2 + 63 (62.0) 39 (38.2) 48 (47.0) 54 (53.0)
Nottingham Prognostic Index
 GPG 155 (84.0) 29 (16.0)  < 0.0001
(20.523)
117 (63.0) 67 (37.0) 0.002
(12.257) MPG 253 (68.0) 122 (32.0) 187 (49.0) 188 (51.0)
 PPG 72 (64.0) 40 (36.0) 51 (46.0) 61 (56.0)
Lymphovascular invasion (LVI)
 Negative/probable 230 (73.0) 86 (27.0) 0.445
(0.584)
180 (57.0) 136 (43.0) 0.031
(4.669) Definite 157 (70.0) 68 (30.0) 107 (48.0) 118 (52.0)
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including tumour size, histological grade, nodal stage, and 
proliferative fraction as assessed by Ki67.
Genomic investigation and pathway analysis
To understand the molecular biology of MMP9 protein 
expression as an end point, the subset of the Notting-
ham series that was included in the METABRIC dataset 
(n = 113) were used for DGE analysis. The dichotomisa-
tion of cases into negative/low versus high groups was 
based on the dichotomisation of MMP9 protein expression. 
Cytoplasmic MMP9 expression displayed high expression 
in 36/113 cases (32%), while, stromal MMP9 showed high 
expression in 53/113 cases (47%). DGE analysis identi-
fied 1630 significantly differentially expressed genes 
associated with cytoplasmic MMP9 expression, with 
decreased cytoplasmic MMP9 expression displayed 720 
upregulated and 910 downregulated genes, respectively. 
Stromal MMP9 showed 1480 differentially regulated 
genes, reduced stromal MMP9 expression was associated 
with 667 upregulated and 813 downregulated differentially 
expressed genes (Fig. 3). The overlapping DGEs between 
(A) low Vs high MMP9 cytoplasmic expression, and 
(B) low Vs high MMP9 stromal expression revealed 277 
upregulated differentially expressed genes and 276 down-
regulated differentially expressed genes (Fig. 4). The com-
mon differentially expressed genes (n = 553) which were 
significantly associated with ECM related gene ontologies 
(Fig. 5, Table 6).
Table 2  Associations between MMP9 protein expression and other biomarkers in the breast cancer cohort
Significant p values are highlighted in bold
Parameters MMP9 cytoplasmic (C+) expression MMP9 stromal (S+) expression
Negative/low 
expression n (%)
High expression n (%) p value (χ2) Negative/low 
expression n (%)
High expression n (%) p value (χ2)
Oestrogen (ER) status
 Negative 107 (59.0) 74 (41.0)  < 0.0001
(18.402)
69 (38.0) 112 (62.0)  < 0.0001
(20.194) Positive 373 (76.0) 118 (24.0) 283 (58.0) 208 (42.0)
Progesterone (PR) status
 Negative 182 (66.0) 95 (34.0) 0.005
(7.860)
125 (45.0) 152 (55.0) 0.002
(9.936 Positive 284 (76.0) 91 (24.0) 216 (58.0) 159 (42.0)
Human epidermal growth factor receptor 2 (HER2)
 Negative 410 (74.0) 146 (26.0) 0.009
(6.784)
302 (54.0) 254 (46.0) 0.150
(2.077) Positive 63 (61.0) 40 (39.0) 48 (47.0) 55 (53.0)
Epidermal Growth Factor Receptor (EGFR)
 Negative 385 (74.0) 137 (26.0) 0.024
(5.069)
285 (55.0) 237 (45.0) 0.016
(5.856) Positive 85 (64.0) 48 (36.0) 57 (43.0) 76 (57.0)
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)
 Negative 93 (79.0) 25 (21.0) 0.052
(3.787)
72 (61.0) 46 (39.0) 0.039
(4.271) Positive 287 (70.0) 125 (30.0) 207 (50.0) 205 (50.0)
Ki67
 Negative 156 (77.0) 47 (23.0) 0.050 (3.858)) 126 (62.0) 77 (38.0) 0.004
(8.474) Positive 222 (69.0) 100 31.0) 158 (49.0) 164 (51.0)
Cytokeartin5/6 (CK5/6)
 Negative 324 (71.0) 127 (29.0) 0.080
(3.071)
241 (53.0) 210 (47.0) 0.099
(2.726) Positive 57 (63.0) 34 (37.0) 40 (44.0) 51 (56.0)
Cytokeartin17 (CK17)
 Negative 309 (73.0) 113 (27.0) 0.001
(10.888)
225 (53.0) 197 (47.0) 0.395
(0.724) Positive 42 (55.0) 35 (45.0) 37 (48.0) 40 (52.0)
Cell division cycle 42 (CDC42)
 Negative 196 (76.0) 60 (24.0) 0.003
(9.046)
138 (54.0) 118 (46.0) 0.892 (0.018)
 Positive 126 (64.0) 72 (36.0) 108 (55.0) 90 (45.0)
Cluster of differentiation 44 (CD44)
 Negative 109 (77.0) 32 (23.0) 0.025
(5.027)
77 (55.0) 64 (45.0) 0.996
(0.001) Positive 167 (67.0) 84 (33.0) 137 (55.0) 114 (45.0)
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Discussion
Several studies have examined the roles of MMP9 in can-
cer development, progression, and its impact on patients’ 
survival and prognosis [2, 36–38]. Limited research 
however has been done to demonstrate the mRNA, copy 
number alterations and protein expression of MMP9 in 
BC and correlate the findings with clinicopathologic vari-
ables and cytoskeletal modulators in an extended cohort 
of BC patients. The cytoskeleton connects the cytoplasm 
and the plasma membrane and responds to external stim-
uli and signals. Cells that grow abnormally and acquire 
the ability to migrate and invade are the hallmark of 
Fig. 2  Kaplan–Meier plots of MMP9 expression and breast cancer 
patient outcome. At protein level a cytoplasmic MMP9, b stromal 
MMP9, c combined cytoplasmic and stromal MMP9 expression. 
Combined analysis of cytoplasmic and stromal MMP9 demonstrated 
that tumours with high cytoplasmic and stromal expression were 
associated with shorter  BCSS. At transcriptomic level (d) META-
BRIC cohort MMP9 gain, e MMP9 mRNA and f Breast Cancer Gene-
Expression Miner v4.0-Kaplan–Meier plots of MMP9 gene expres-
sion. Outcome analysis revealed that high expression of MMP9 was 
associated with shorter patient survival
Table 3  Univariate and 
multivariate analysis of 
MMP9 (C+ & S+) expression 
compared with tumour stage, 
grade, size, Ki67 and ER 
status for breast cancer-specific 
survival
Significant p values highlighted in bold
Variable Breast cancer-specific survival
Univariate Multivariate
HR 95%CI p value HR 95%CI p value
Whole cohort
 Stage 2.7 1.8–3.2  < 0.0001 2.4 1.8–3.2  < 0.0001
 Grade 2.7 2.4–3.3  < 0.0001 2.1 1.3- 3.3 0.001
 Tumour size 2.1 1.8–2.5  < 0.0001 1.5 0.9–2.3 0.068
 ER 1.0 0.9–1.1  < 0.0001 0.9 0.9–1.0 0.335
 Ki67 2.6 2.1–3.3  < 0.0001 1.5 0.8–2.4 0.155
 MMP9(C+) 1.5 1.1–2.0 0.013 1.6 1.1–2.3 0.026
 MMP9 (S+) 1.3 1.0–1.8 0.060 1.2 0.8–1.8 0.305
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metastatic cancers. Alteration of cytoskeletal structure is 
very important in cell invasion, migration, adhesion and 
change in morphology [39]. The degradation of ECM by 
MMP family members including MMP9 is believed to 
favour tumour growth, metastasis, invasion and cytoskel-
etal re-organisation [40]. Thus, the link between MMP9 
and cytoskeletal modulators may have important clini-
cal implications. The aim of this study was to determine 
whether elevated MMP9 expression at mRNA and pro-
tein level correlated with tumour grade, BC morphology, 
cytoskeletal modulators and patient outcome using a large 
clinical data set with long-term follow-up.
High MMP9 expression was associated with an increase 
in cell proliferation activity indicated by high expression of 
Ki67, which is associated with poor patient outcome [41]. 
Also, elevated levels of CK17 was associated with increased 
expression of MMP9. Breast tumours expressing CK17 and 
CK5/6 show high mortality rate which clearly implicate a 
role in tailoring treatment decisions [22]. These findings 
strengthen the putative role of MMP9 in tumour progression.
Table 5  Associations between 
MMP9 mRNA and ECM 
associated markers







Matrix metallopeptidase 1 (MMP1)
 Negative 820 (60.0) 559 (40.0)  < 0.0001 (164.48)
 Positive 169 (28.0) 432 (72.0)
Matrix metallopeptidase 2 (MMP2)
 Negative 604 (55.0) 505 (45.0)  < 0.0001 (20.548)
 Positive 385 (44.0) 486 (56.0)
Matrix metallopeptidase 7(MMP7)
 Negative 583 (59.0) 407 (41.0)  < 0.0001 (63.291)
 Positive 406 (41.0) 584 (59.0)
Matrix metallopeptidase 11 (MMP11)
 Negative 551 (56.0) 439 (44.0)  < 0.0001 (25.796)
 Positive 438 (44.0) 552 (56.0)
Matrix metallopeptidase 14 (MMP14)
 Negative 587 (54.0) 503 (46.0) 0.0001 (14.782)
 Positive 402 (45.0) 488 (55.0)
Matrix metallopeptidase 15 (MMP15)
 Negative 671 (55.0) 544 (45.0)  < 0.0001 (35.026)
 Positive 318 (42.0) 447 (58.0)
Collagen Type XXVII Alpha 1 (COL27A1)
 Negative 524 (53.0) 466 (47.0) 0.008
(7.032) Positive 465 (47.0) 525 (53.0)
Collagen Type XXIII Alpha 1 (COL23A1)
 Negative 598 (53.0) 531 (47.0) 0.003 (8.962)
 Positive 391 (46.0) 456 (54.0)
Collagen Type XXI Alpha 2 (COL11A2)
 Negative 576 (51.0) 534 (49.0) 0.045 (4.019)
 Positive 411 (47.0) 457 (53.0)
Transforming Growth Factor Beta 1(TGFBeta1)
 Negative 672 (67.0) 338 (33.0)  < 0.0001
(226.83) Positive 317 (32.0) 653 (68.0)
Cell Division Cycle 42 (CDC42)
 Negative 496 (53.0) 431 (47.0) 0.004 (8.325)
 Positive 495 (47.0) 558 (53.0)
Cell surface adhesion receptor (CD44)
 Negative 498 (50.0) 502 (50.0) 0.893
(0.018) Positive 491 (50.1) 489 (49.9)
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The EGFR/PIK3 signalling pathway plays important roles 
in tumour progression, and these pathways are reported to 
be frequently altered in BC [42]. We observed that high 
MMP9 expression was positively associated with EGFR 
and PIK3 signalling pathways. Elevated EGFR/PIK3 expres-
sion was associated with poor patient outcome in TNBC 
and Luminal B subtypes. Moreover, the PIK3/Akt pathway 
triggers MMP9 secretion and promotes cell invasion [43]. 
This implies that MMP9 could have a role in tumourigenic 
pathways.
MMP9 expression levels were positively associated with 
the expression of CDC42. CDC42 is a member of the Rho 
family of GTPases, which plays a role in many of the cel-
lular processes that are associated with tumour progression, 
such as cell migration, proliferation, cytoskeletal control 
and vesicular trafficking [44]. A study conducted by Sipes 
and colleagues; revealed that, CDC42 deletion significantly 
reduced MMP9 activity. CDC42 is associated with forma-
tion of invadopodia, which can act as ‘guiding’ structures 
to pave the way for further cytoskeletal protrusions [45, 46]. 
Moreover, in vitro silencing of MMP9 decreased the migra-
tory activity in Adenoid Cystic Carcinoma cells [47]. PIK3 
and CDC42 mediate a positive feedback loop to regulate the 
tumour progression role [48]. Investigating the functional 
role of MMP9 in regulating the PIK3/CDC42 positive feed-
back loop in BC, might reveal a new role for MMP9 in the 
promotion of migration and invasion.
CD44 plays a major role in modulating migration/inva-
sion processes during tumour advancement. Formation of 
CD44-MMP9 complex in prostate cancer promotes cellular 
Fig. 3  Differentially expressed genes associated with MMP9 cyto-
plasmic and stromal expression. a Cases depicting MMP9 cytoplas-
mic protein expression in tumour cells. b cases depicting f MMP9 
protein expression the associated stroma of tumour cells. DGE: dif-
ferentially expressed genes, C: cytoplasmic expression, S: stromal 
expression, (↓): down regulated genes, (↑) up regulated genes. (−) 
cases harbouring low expression of MMP9
Fig. 4  Overlapping differentially expressed genes associated with 
MMP9 cytoplasmic and stromal expression. Cases depicting: a down 
regulation of MMP9 protein expression on both the cytoplasmic 
and associated stroma of tumour cells. b Overlapping differentially 
expressed genes between cases depicting up-regulation of MMP9 
protein expression on both the cytoplasm and associated stroma of 
tumour cells. DGE: differentially expressed genes, C: cytoplasmic 
expression, S: stromal expression, ↓: down regulated genes, ↑ up reg-
ulated genes
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motility and ECM invasion [49]. High MMP9 expression 
was positively associated with CD44 in our study. MMP9 
acts as a processing enzyme for CD44 which promotes cell 
motility and, transcriptional knockdown of MMP9 inhib-
its this interaction [50]. Further studies will be needed to 
unravel the mechanisms by which MMP9 drives CD44 
mediated invasion and tumour progression.
LVI is the presence of cancer cells in lymph vessels and is 
linked with a poor outcome in BC [51]. Daniele et al.; [52] 
showed that high levels of MMP9 expression was found in 
BC tumours with positive sentinel lymph nodes. The sentinel 
node is the proximal lymph node affected by metastatic cells 
since it is the first barrier receiving lymphatic drainage from 
the tumour. In the event of LVI, interactions between ECM 
and stromal non-tumoural cells induce migration, inva-
sion and metastasis. Moreover, stromal fibroblast reported 
to secrete MMP9, which in turn may activate tumour cells 
[53]. Lymphatic networks within lymph nodes spread out 
before the onset of metastasis [54]. Although in our study we 
observed a weak association with stromal MMP9 and LVI, it 
warrants further investigations. Evaluation of stromal MMP9 
expression may provide valuable information regarding the 
early LVI events.
The oncogenic expression of HER2 induces BC dis-
ease progression and invasiveness, which is hypothesised 
to increase MMP9 activity [53]. In this study, high MMP9 
mRNA expression was associated with poor prognostic 
parameters including higher tumour grade, ER-/PR-, HER 
2 + tumours and TNBC tumours. MMP9 was also highly 
expressed in basal type tumours over luminal A and luminal 
B tumours. This is consistent with another study which found 
MMP9 as differentially expressed between molecular sub-
sets of tumours and as a feature of TNBC and HER2 + BCs 
[55]. Increased MMP9 expression was associated with the 
poor prognostic category of the NPI. Hence, as observed 
in our study, MMP9 is a marker indicative of unfavourable 
prognosis in BC. Stromal invasion requires degradation of 
the basement membrane. MMP9 cleave the basement mem-
brane type IV collagen and promote tumour invasion and 
metastasis [56, 57]. The correlation between high expression 
of MMP9 and collagen type XXVIIα1, XXIIIα1, XXIα2 may 
also induce basement degradation. Collagens, matricellular 
proteins and CDC42 at mRNA level showed strong posi-
tive association with MMP9. Results on pathway analysis 
confirmed the significant association with collagens, extra-
cellular matrix and cytoskeletal part gene ontologies. This 
implies that MMP9 plays a role in tumourigenic pathways 
and could be a marker of poor prognosis in BC.
This study reveals that MMP9 at both proteomic and 
transcriptomic levels is associated with poor prognostic 
characteristics and short-term survival outcomes in BC. 
Cytoplasmic MMP9 expression on its own and combined 
Fig. 5  Pathway analysis for 
gene ontology significantly 
associated with cytoplasmic 
and stromal MMP9 protein 
expression. The gene panel were 
significantly associated with 
extracellular matrix related gene 
ontologies
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cytoplasmic and stromal expression was predicative for 
shorter BCSS in the whole cohort, MMP9 did not show 
any association with patient outcome. Stromal cell genetic 
stability plays significant role in modulating the tumour 
microenvironment contributing to drug resistance and 
tumour relapse [58]. Moreover, expression of tumour 
markers in the stroma is found to be closely associ-
ated with tumour progression and patient outcome [59]. 
These findings suggest that MMP9 in both stromal cells 
and tumour cells might play an important role in the BC 
progression. In agreement with our study high expres-
sion of MMP9 was associated with poor patient survival 
[60]. Thus, the current study provides definitive evidence 
that MMP9 is an independent prognostic marker of poor 
short-term clinical outcome in primary BC and supports 
further mechanistic and translational studies to target 
MMP9.
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